Table 1.
General characteristics at baseline and clinical findings during follow-up of the study population (n = 54)
| Parameter | |
|---|---|
| Age (years), median [IQR] | 60 [58–63] |
| Sex, no. (%) | |
| M/F | 46 (85)/8 (15) |
| BMI, kg/m2, median [IQR] | 27 [25.5–28.1] |
| Blood pressure (mmHg), median [IQR] | |
| Systolic | 130 [120–131.2] |
| Diastolic | 80 [70–80] |
| Hypertension, no. (%) | 15 (28) |
| Smoke, no. (%) | 43 (80) |
| Cholesterol (mg/dL), median [IQR] | |
| Total | 172 [149.5–189] |
| HDL | 42.5 [35–51] |
| LDL | 103 [68–128] |
| Triglycerides (mg/dL), median [IQR] | 127 [105.2–151.5] |
| Glycemia (mg/dL), median [IQR] | |
| Baseline | 87 [80–90.2] |
| 2 h | 109 [93–126.7] |
| Glycated hemoglobin (%), median [IQR] | 5.2 [5.1–5.5] |
| Insulin (µU/mL), median [IQR] | 3.8 [3–6] |
| HOMA IR, median [IQR] | 0.78 [0.59–1.31] |
| Creatinine (mg/dL), median [IQR] | 1 [0.87–1.1] |
| Hemoglobin (mg/dL), median [IQR] | 14.3 [13.3–15.2] |
| Adiponectin (µg/mL), median [IQR] | 11 [9.7–13.2] |
| Adiponectin, no. (%) | |
| Pathologic | 13 (24) |
| Resistin (ng/mL), median [IQR] | 7 [4–9] |
| Resistin, no. (%) | |
| Pathologic | 8 (15) |
| TNF-alpha (ng/mL), median [IQR] | 8.5 [7–11] |
| TNF-alpha, no. (%) | |
| Pathologic | 6 (11) |
| Site of stenosis at first PCI, no. (%) | |
| IVA | 25 (46) |
| CX | 10 (19) |
| DX | 19 (35) |
| Follow-up duration (months), median [IQR] | 29.5 [14.7–34] |
| Re-PCI, no. (%) | 4 (7) |
| Time re-PCI, median [IQR] | 8.5 [4–15.75] |
| Site of re-PCI, no. (%) | |
| IVA | 3 (75) |
| CX | 0 (−) |
| DX | 1 (25) |
| New PCI, no. (%) | 5 (9) |
| Time new PCI, median [IQR] | 29 [IQR 12–33.5] |
| Site of new-PCI, no. (%) | |
| IVA | 2 (40) |
| CX | 1 (20) |
| DX | 2 (40) |
| Death, no. (%) | |
| Cardiovascular/other causes | − /1 (2) |